Skip to main content

Table 1 Baseline Characteristics of Participants (N = 703)

From: Mortality in homeless people enrolled in the French housing first randomized controlled trial: a secondary outcome analysis of predictors and causes of death

Characteristics

Total

(n = 703)

HF Group

(n = 353)

TAU Group (n = 350)

p-value

Gender, No. (%)

   

0.10

 Men

580 (82.5)

283 (80.2)

297 (84.9)

 

 Women

123 (17.5)

70 (19.8)

53 (15.1)

 

Age mean (SD), y

38.7 (10.0)

38.1 (9.7)

39.4 (10.3)

0.09

Education, No. (%)

   

0.52

 Less than high school (<bac)

490 (73.0)

249 (71.9)

241 (74.1)

 

 Completed or postsecondary school

181 (27)

97 (28.0)

84 (25.8)

 

Housing status, No. (%)

   

0.04

 Precariously housed

238 (34.0)

107 (30.3)

131 (37.6)

 

 Absolutely homeless

463 (66.0)

246 (69.7)

217 (62.3)

 

Lifetime duration of homelessness, Median (IQR), months

72.0 (33–144)

72 (24–144)

72 (30–144)

0.99

Mental disorder, No. (%)

   

0.81

 Schizophrenia

487 (69.3)

243 (68.8)

244 (69.7)

 

 Bipolar

216 (30.7)

110 (31.1)

106 (30.2)

 

CGI Score mean (SD)

4.6 (1.3)

4.6 (1.3)

4.6 (1.2)

0.64

MCAS score mean (SD)

51.1 (7.2)

51.2 (7.5)

51 (7.0)

0.20

PCS SF-36 score mean (SD)

50.1 (11.6)

50.3 (10.7)

50.2 (12.0)

0.610

MCS SF-36 score mean (SD)

34.6 (10.0)

34.8 (9.8)

34.4 (10.2)

0.497

Violent victimization, No. (%)

225 (33.3)

116 (33.2)

109 (33.4)

0.957

Nonviolent victimization, No. (%)

356 (52.7)

190 (54.4)

166 (50.9)

0.360

Hospitalization, No. (%)

408 (60.8)

215 (61.8)

193 (59.8)

0.591

Taking medicines, No. (%)

513 (73.0)

263 (74.5)

250 (71.4)

0.359

MOUD

136 (19.3)

64 (18.1)

72 (20.6)

0.413

Psychotropic drugs

473 (64.3)

241 (68.3)

232 (66.3)

0.575

Other treatments

55 (7.8)

38 (10.8)

17 (4.9)

0.004

Mini International neuropsychiatric interview

 Substance Dependence, No. (%)

322 (53.7)

170 (48.5)

152 (44.0)

0.23

 Alcohol Dependence, No. (%)

274 (39.3)

152 (43.5)

122 (35.1)

0.02

  1. HF Housing First, TAU Treatment-as-usual, SD standard deviation, IQR interquartile range, CGI Clinical Global Impression scale, MCAS Multnomah Community Ability Scale, SF-36 Medical Outcomes Study 36-iIem Short-Form Health Survey, PCS physical composite score, MCS mental composite score; MOUD Medications for Opioid Use Disorder, MINI Mini International neuropsychiatric interview